Advertisement

Lung

pp 1–7 | Cite as

Pirfenidone Therapy for Familial Pulmonary Fibrosis: A Real-Life Study

  • David BennettEmail author
  • Rosa Metella Refini
  • Maria Lucia Valentini
  • Annalisa Fui
  • Antonella Fossi
  • Maria Pieroni
  • Maria Antonietta Mazzei
  • Paola Rottoli
INTERSTITIAL LUNG DISEASE

Abstract

Introduction

Familial pulmonary fibrosis (FPF) is defined as an idiopathic diffuse parenchymal lung disease affecting two or more members of the same primary biological family. The aim of this study was to compare disease progression and tolerance to pirfenidone in a population of FPF patients who presented with radiological and/or histological evidence of UIP, and a group of idiopathic pulmonary fibrosis (IPF) patients.

Methods

Seventy-three patients (19 with FPF and 54 with IPF) were enrolled and data were collected retrospectively at 6, 12 and 24 months follow-up.

Results

FPF patients were statistically younger and more frequently females. A significantly greater decline in FVC and DLCO was recorded in FPF than in IPF patients at 24 months follow-up. At the 6-min walking test, walked distance declined significantly in FPF patients than IPF at 24 months. No statistically significant differences in drug tolerance or side effects were recorded between groups.

Conclusion

Different rate of progression was observed in patients with IPF and FPF on therapy with pirfenidone; our findings may not be due to lack of effectiveness of therapy, but to the different natural history and evolution of these two conditions. Pirfenidone was well tolerated by FPF and IPF patients. Specific unbiased randomized clinical trials on larger populations to validate our preliminary exploratory results are needed.

Keywords

Pirfenidone Familial pulmonary fibrosis Idiopathic pulmonary fibrosis Therapy 

Notes

Compliance with Ethical Standards

Conflict of interest

Dr. Bennett reports personal fees from Boehringer Ingelheim, personal fees from Roche, personal fees from Biotest, outside the submitted work. Prof. Rottoli reports personal fees and other from Roche, personal fees from Boehringer ingelheim, grants and personal fees from Novartis, personal fees from TEVA, other from Menarini, outside the submitted work. Dr. Rosa Metella Refini, Dr. Maria Lucia Valentini, Dr. Annalisa Fui, Dr. Antonella Fossi, Dr. Maria Pieroni and Prof. Maria Antonietta Mazzei and have nothing to disclose.

Supplementary material

408_2019_203_MOESM1_ESM.docx (41 kb)
Supplementary material 1 (DOCX 40 KB)

References

  1. 1.
    Travis WD, Costabel U, Hansell DM, King TE Jr, Lynch DA, Nicholson AG, Ryerson CJ, Ryu JH, Selman M, Wells AU, Behr J, Bouros D, Brown KK, Colby TV, Collard HR, Cordeiro CR, Cottin V, Crestani B, Drent M, Dudden RF, Egan J, Flaherty K, Hogaboam C, Inoue Y, Johkoh T, Kim DS, Kitaichi M, Loyd J, Martinez FJ, Myers J, Protzko S, Raghu G, Richeldi L, Sverzellati N, Swigris J, Valeyre D, ATS/ERS Committee on Idiopathic Interstitial Pneumonias (2013) An official American Thoracic Society/European Respiratory Society statement: update of the international multidisciplinary classification of the idiopathic interstitial pneumonias. Am J Respir Crit Care Med 188(6):733–748CrossRefPubMedCentralGoogle Scholar
  2. 2.
    Lee HL, Ryu JH, Wittmer MH, Hartman TE, Lymp JF, Tazelaar HD, Limper AH (2005) Familial idiopathic pulmonary fibrosis: clinical features and outcome. Chest 127(6):2034–2041CrossRefGoogle Scholar
  3. 3.
    Ravaglia C, Tomassetti S, Gurioli C, Piciucchi S, Dubini A, Gurioli C, Casoni GL, Romagnoli M, Carloni A, Tantalocco P, Buccioli M, Chilosi M, Poletti V (2014) Features and outcome of familial idiopathic pulmonary fibrosis. Sarcoidosis Vasc Diffuse Lung Dis 31(1):28–36Google Scholar
  4. 4.
    Mathai SK, Yang IV, Schwarz MI, Schwartz DA (2015) Incorporating genetics into the identification and treatment of idiopathic pulmonary fibrosis. BMC Med 13:191CrossRefPubMedCentralGoogle Scholar
  5. 5.
    Garcia CK (2011) Idiopathic pulmonary fibrosis: update on genetic discoveries. Proc Am Thorac Soc 8(2):158–162CrossRefPubMedCentralGoogle Scholar
  6. 6.
    Diaz de Leon A, Cronkhite JT, Katzenstein AL, Godwin JD, Raghu G, Glazer CS, Rosenblatt RL, Girod CE, Garrity ER, Xing C, Garcia CK (2010) Telomere lengths, pulmonary fibrosis and telomerase (TERT) mutations. PLoS ONE 5(5):e10680CrossRefPubMedCentralGoogle Scholar
  7. 7.
    Nogee LM, Dunbar AE III, Wert SE, Askin F, Hamvas A, Whitsett JA (2001) A mutation in the surfactant protein C gene associated with familial interstitial lung disease. N Engl J Med 344(8):573–579CrossRefGoogle Scholar
  8. 8.
    Campo I, Zorzetto M, Mariani F, Kadija Z, Morbini P, Dore R, Kaltenborn E, Frixel S, Zarbock R, Liebisch G, Hegermann J, Wrede C, Griese M, Luisetti M (2014) A large kindred of pulmonary fibrosis associated with a novel ABCA3 gene variant. Respir Res 15:43CrossRefPubMedCentralGoogle Scholar
  9. 9.
    King TE Jr, Bradford WZ, Castro-Bernardini S, Fagan EA, Glaspole I, Glassberg MK, Gorina E, Hopkins PM, Kardatzke D, Lancaster L, Lederer DJ, Nathan SD, Pereira CA, Sahn SA, Sussman R, Swigris JJ, Noble PW, ASCEND Study Group (2014) A phase 3 trial of pirfenidone in patients with idiopathic pulmonary fibrosis. N Engl J Med 370:2083–2092CrossRefGoogle Scholar
  10. 10.
    Noble PW, Albera C, Bradford WZ, Costabel U, Glassberg MK, Kardatzke D, King TE Jr, Lancaster L, Sahn SA, Szwarcberg J, Valeyre D, du Bois RM, CAPACITY Study Group (2011) Pirfenidone in patients with idiopathic pulmonary fibrosis (CAPACITY): two randomized trials. Lancet 377:1760–1769CrossRefGoogle Scholar
  11. 11.
    Richeldi L, du Bois RM, Raghu G, Azuma A, Brown KK, Costabel U, Cottin V, Flaherty KR, Hansell DM, Inoue Y, Kim DS, Kolb M, Nicholson AG, Noble PW, Selman M, Taniguchi H, Brun M, Le Maulf F, Girard M, Stowasser S, Schlenker-Herceg R, Disse B, Collard HR, INPULSIS Trial Investigators (2014) Efficacy and safety of nintedanib in idiopathic pulmonary fibrosis. N Engl J Med 370(22):2071–2082CrossRefGoogle Scholar
  12. 12.
    Raghu G, Remy-Jardin M, Myers JL, Richeldi L, Ryerson CJ, Lederer DJ, Behr J, Cottin V, Danoff SK, Morell F, Flaherty KR, Wells A, Martinez FJ, Azuma A, Bice TJ, Bouros D, Brown KK, Collard HR, Duggal A, Galvin L, Inoue Y, Jenkins RG, Johkoh T, Kazerooni EA, Kitaichi M, Knight SL, Mansour G, Nicholson AG, Pipavath SNJ, Buendía-Roldán I, Selman M, Travis WD, Walsh S, Wilson KC, American Thoracic Society, European Respiratory Society, Japanese Respiratory Society, and Latin American Thoracic Society (2018) Diagnosis of idiopathic pulmonary fibrosis. An official ATS/ERS/JRS/ALAT clinical practice guideline. Am J Respir Crit Care Med 198(5):e44–e68CrossRefGoogle Scholar
  13. 13.
    Meyer KC, Raghu G, Baughman RP, Brown KK, Costabel U, du Bois RM, Drent M, Haslam PL, Kim DS, Nagai S, Rottoli P, Saltini C, Selman M, Strange C, Wood B, American Thoracic Society Committee on BAL in Interstitial Lung Disease (2012) An official American Thoracic Society clinical practice guideline: the clinical utility of bronchoalveolar lavage cellular analysis in interstitial lung disease. Am J Respir Crit Care Med 185(9):1004–1014.  https://doi.org/10.1164/rccm.201202-0320ST CrossRefGoogle Scholar
  14. 14.
    Harari S, Caminati A, Albera C, Vancheri C, Poletti V, Pesci A, Luppi F, Saltini C, Agostini C, Bargagli E, Sebastiani A, Sanduzzi A, Giunta V, Della Porta R, Bandelli GP, Puglisi S, Tomassetti S, Biffi A, Cerri S, Mari A, Cinetto F, Tirelli F, Farinelli G, Bocchino M, Specchia C, Confalonieri M (2015) Efficacy of pirfenidone for idiopathic pulmonary fibrosis: an Italian real life study. Respir Med 109(7):904–913CrossRefGoogle Scholar
  15. 15.
    Bennett D, Mazzei MA, Squitieri NC, Bargagli E, Refini RM, Fossi A, Volterrani L, Rottoli P (2017) Familial pulmonary fibrosis: clinical and radiological characteristics and progression analysis in different high resolution-CT patterns. Respir Med 126:75–83CrossRefGoogle Scholar
  16. 16.
    King CS, Nathan SD (2017) Idiopathic pulmonary fibrosis: effects and optimal management of comorbidities. Lancet Respir Med 5(1):72–84CrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2019

Authors and Affiliations

  1. 1.Respiratory Diseases and Lung Transplantation Unit, Azienda Ospedaliera Universitaria Senese (AOUS) - Department of Medical and Surgical Sciences & NeurosciencesUniversity of SienaSienaItaly
  2. 2.Diagnostic Imaging Unit, Azienda Ospedaliera Universitaria Senese (AOUS) - Department of Medical and Surgical Sciences & NeurosciencesUniversity of SienaSienaItaly

Personalised recommendations